New hope for recurrent brain cancer? early trial targets immune suppression

This early-phase study tested a combination of two drugs (low-dose capecitabine and bevacizumab) in 12 people whose glioblastoma brain tumor had come back or continued growing despite prior treatment. The goal was to see if the drugs could reduce certain immune cells (MDSCs) that help the tumor hide from the body's defenses. The study focused on safety and biological effects, not on curing the disease.